2025年美国临床肿瘤学会(ASCO)年会于当地时间5月30日至6月3日在芝加哥盛大举行。由上海长征医院肖建如、杨诚教授团队开展的“卡瑞利珠单抗联合阿帕替尼治疗难治性脊索瘤的单臂II期临床研究”结果以口头报告的形式亮相大会现场(摘要号：11503)[ ...

Longitudinal plasma proteomic analysis: A monitoring strategy for NSCLC patients treated with immunotherapy. Radiomic phenotypes of tumor angiogenesis compared with PD-L1 in pre-treatment prediction ...

Chitinase 3-like-1 (CHI3L1): A potential prognostic biomarker for immunotherapy (IO) in non-small cell lung cancer (NSCLC). Obesity paradox in non-small cell lung cancer (NSCLC) patients on immune ...

癌度医学临床招募资讯微信群（点击）肿瘤治疗一个常见的误区是：“用的药越多，治疗肿瘤的效果越好”，但事实并非如此，任何药物都有不良反应，如果不能对症联合药物反而适得其反。最近的LEAP-006临床研究发现，在治疗晚期非小细胞肺癌时，在PD-1联合化疗的 ...

Daiichi and MSD have voluntarily withdrawn the BLA in the US for their patritumab deruxtecan for treating non-small cell lung ...

The FDA biologics license application for patritumab deruxtecan in EGFR+ NSCLC has been withdrawn following discussions with ...

MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and in combination ...

MK-1084, Merck’s investigational KRAS G12C inhibitor, showed a manageable safety profile along with antitumor activity in the ...

The first half of this year has been riddled with market volatility and geopolitical tension. But 2025’s American Society of ...

A 14-gene molecular assay could help predict which patients with early-stage non-small cell lung cancer will benefit from ...

The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...